Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone levels. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension. The company has plans for the continued research and development of lorundrostat in hypertension and other potential indications. Mineralys Therapeutics was founded in 2019, and is headquartered in Radnor, Pennsylvania.

Register for Details

For more details on financing and valuation of private companies similar to Mineralys before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Mineralys

To invest in Mineralys pre-IPO

Can you invest in Mineralys pre-IPO?

You may invest in Mineralys as it is a public company listed on the NASDAQ with ticker MLYS. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Mineralys before it goes public?

You can no longer sell shares of Mineralys on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Mineralys shares?

Forge can no longer determine the value of Mineralys shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Mineralys a publicly traded company?

Mineralys became a public company following its IPO on 02/14/2023 and is now traded on the NASDAQ under the ticker MLYS.

To learn more about Mineralys potential IPO

Will Mineralys go IPO?

Mineralys became a public company following its IPO on 02/14/2023 and is now traded on the NASDAQ under the ticker MLYS.

What is Mineralys’ IPO price?

The IPO price of Mineralys is not currently available.

When was Mineralys founded?

Mineralys was founded in 2019.

What is Mineralys funding to date?

Mineralys has raised $159.18MM to date.

Who are Mineralys’s major investors?

Adams Street Partners
Ra Capital Management
Rock Springs Capital
Samsara Biocapital
RTW Investments
Andera Partners

Mineralys Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
06/08/2022 Series B $118MM $xx.xx $26.74B Adams Street Partners, Andera Partners, Boulder Ventures, Catalys Pacific, Hbm Healthcare Investments, Healthcor Management, Ra Capital Management, Rock Springs Capital, Rtw Investments, Samsara Biocapital, Sectoral Asset Management, Sr One Capital Management, Ysis Capital
Price per Share
$xx.xx
Shares Outstanding
136,510,868
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Adams Street Partners, Andera Partners, Boulder Ventures, Catalys Pacific, Hbm Healthcare Investments, Healthcor Management, Ra Capital Management, Rock Springs Capital, Rtw Investments, Samsara Biocapital, Sectoral Asset Management, Sr One Capital Management, Ysis Capital
04/06/2021 Series A $41.18MM $xx.xx $8.24B Adams Street Partners, Catalys Pacific, Hbm Healhcare Investments, Samsara Biocapital
Price per Share
$xx.xx
Shares Outstanding
86,332,216
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
Adams Street Partners, Catalys Pacific, Hbm Healhcare Investments, Samsara Biocapital
Updated on: Nov 23, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.